Table 1.

Baseline characteristics of patients by randomization group

Erlotinib dose
Characteristic25 mg (N = 15)50 mg (N = 15)100 mg (N = 15)
Demographics
 Age (y), mean (SD)63.67 (4.43)62.47 (6.03)60.67 (7.42)
 Male, n (%)13 (87%)14 (93%)10 (67%)
Ethnicity
 Hispanic or Latino, n (%)4 (27%)2 (13%)1 (7%)
 Non-Hispanic or Latino, n (%)8 (53%)11 (73%)10 (67%)
 Unknown, n (%)3 (20%)2 (13%)4 (27%)
 Race-White, n (%)13 (87%)13 (87%)12 (80%)
 Weight (kg), mean (SD)83.66 (16.83)96.42 (19.01)91.14 (29.52)
 NSAID use < 10 d/month, n (%)9 (60.0)9 (60.0)9 (60.0)
Hematology
 Hemoglobin, mean (SD)14.05 (1.06)14.05 (1.66)14.24 (1.19)
 Hematocrit, mean (SD)40.75 (3.19)41.15 (4.27)41.99 (3.56)
 WBC, mean (SD)6.67 (2.27)6.19 (1.36)6.91 (1.97)
 Neutrophils, % mean (SD)61.53 (9.86)61.87 (8.85)60.69 (8.04)
 Lymphocytes, % mean (SD)28.47 (8.21)27.16 (8.14)27.65 (8.75)
 Monocytes, % mean (SD)7.51 (2.7)8.26 (2.83)8.11 (2.31)
 Eosinophils, % mean (SD)1.98 (1.61)2.16 (1.26)2.76 (2.54)
 Basophils, % mean (SD)0.44 (0.37)0.55 (0.4)0.79 (0.32)
 Platelet, mean (SD)226.07 (67.99)224.73 (52.87)230.64 (43.84)
Blood chemistry
 Total protein, mean (SD)6.86 (0.26)6.71 (0.46)6.66 (0.59)
 Albumin, mean (SD)4.16 (0.21)4.01 (0.21)3.91 (0.31)
 BUN, mean (SD)15.67 (2.61)17.2 (9.89)15.07 (4.39)
 Creatinine, mean (SD)0.99 (0.2)1.08 (0.17)1.03 (0.24)
 Bilirubin, direct, mean (SD)0.12 (0.04)0.17 (0.12)0.11 (0.03)
 Bilirubin, total, mean (SD)0.99 (0.4)0.75 (0.3)0.71 (0.24)
 Alkaline phosphatase, mean (SD)69.47 (16.26)60.27 (16.82)64.86 (27.27)
 Sodium, mean (SD)138.67 (2.53)138 (1.77)139.71 (2.92)
 Potassium, mean (SD)4.29 (0.4)4.36 (0.57)4.17 (0.45)
 Chloride, mean (SD)103.67 (3.72)103.67 (3.04)104 (2.83)
 Bicarbonate, mean (SD)26.64 (2.11)27.33 (3.11)28.46 (1.33)
 SGOT/AST, mean (SD)24.07 (4.48)26.8 (9.07)27.14 (9.05)
 SGPT/ALT, mean (SD)25.33 (9.63)25.87 (14.35)27.14 (11.09)